Hitachi Medical Systems Europe Holding AG
Storys zum Thema Medizin, Gesundheit
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Carag First-ever Septal Occluder With Bioresorbable, Metal-free Framework Available to Patients Through New European Registry
Baar, Switzerland and Berlin (ots/PRNewswire) - First 3-year-old patient successfully implanted and discharged from hospital in Berlin CARAG AG, a Swiss privately held medical device development company, announced today the successful implantation of the first-ever transcatheter septal occluder with bioresorbable, ...
mehrSenzer Secures US Clinical Data Package for the Treatment of Chemotherapy Induced Adverse Events
London (ots/PRNewswire) - Senzer has secured the Investigational New Drug application and data package for its ongoing FDA registration programme from its former US strategic partner and will now push ahead to get its cannabinoid respiratory device approved for treating side effects induced by anti-cancer treatments ...
mehrERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Darmstadt, Germany (ots/PRNewswire) - Approval is for ERBITUX® in combination with platinum-based therapy with fluorouracil for the first-line treatment of R/M SCCHN Pivotal Phase III study shows significant improvements with ERBITUX® in combination with platinum-based therapy with fluorouracil in response rate, ...
mehrSOPHiA GENETICS' Board of Directors Elects Troy Cox as New Chairman
Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that former Foundation Medicine CEO Troy Cox has been elected as Chairman of the Board of Directors, effective March 1, 2020. He is replacing Antoine Duchateau, who has served as chairman since 2013 and will continue as a board member. Cox joined the ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Decision time predicts the risk of depression relapse
Bern (ots) - In a study supported by the Swiss National Science Foundation, researchers have shown that it is possible to predict the risk of relapsing into depression after stopping antidepressant medication. People who relapse take longer to decide how much effort to invest for a reward. Depressive disorder is a major public health problem with an unpredictable course. It often recurs, with episodes of depression ...
mehrNew Data Show Oral Ferric Maltol (FERACCRU®) May Be a Cost-effective Alternative to Intravenous (IV) Carboxymaltose With at Least as Great Benefits in the Quality of Life of Patients With Iron Deficiency Anaemia and Inflammatory Bowel Disease
Amsterdam (ots/PRNewswire) - - Ferric maltol (FM) was associated with substantially lower use of healthcare resources than IV ferric carboxymaltose (FCM) - IV FCMwas linked to greater productivity loss and disruption to patients' work and family life due to the need for clinic-based IV administration - 50% of ...
mehrMSD in Switzerland launches new gender-neutral parental leave policy effective February 1st, 2020
Lucerne (ots) - Following its nomination for an eight time in a row as Top Employer Switzerland, MSD (Merck Sharp & Dohme AG) is delighted to announce the introduction of a new gender-neutral parental leave policy to all its employees within ...
Ein DokumentmehrNorgine B.V. Enters Into Exclusive Licence and Distribution Agreements for the Commercialisation of PLENVU® in a Number of Countries in Latin America, Southern Africa, Central and Eastern Europe
Amsterdam (ots/PRNewswire) - - Norgine to receive upfront payments, undisclosed milestone payments along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries Norgine B.V. (Norgine), a leading European specialist pharmaceutical company, today ...
mehrSMART Medical Systems Launches its G-EYE® 760R Colonoscope in the European Endoscopy Market Through FUJIFILM Europe, Under Strategic Distribution Partnership With FUJIFILM Corporation, to Provide Synergetic Colonoscopy Solution in Fight Against Colon ...
Ra'anana, Israel (ots/PRNewswire) - SMART's G-EYE® 760R colonoscope, incorporating its G-EYE® Balloon Technology designed to increase the detection of cancerous polyps in colonoscopy, will become available by FUJIFILM Europe with its state-of-the-art ELUXEO system, as part of the newly formed strategic ...
mehrHelsana posts outstanding result for 2019
Zürich (ots) - In 2019, Helsana Insurance Company Ltd recorded an outstanding result of CHF 436 million. This comprises a very strong investment performance and a solid underwriting result. Customer growth for 2020 once again clearly exceeded the prior year and the new corporate strategy was successfully launched at the start of 2020. In 2019, Helsana Insurance Company Ltd recorded an outstanding result of CHF 436 ...
mehrOn World Cancer Day, MSD Switzerland Stands United in Support of its Patients
Lucerne (ots) - World Cancer Day every 4th of February is a global uniting movement led by the Union for International Cancer Control (UICC). MSD (Merck Sharp & Dohme) is a proud sponsor of this initiative, joining the conversation to create a groundswell of awareness and action that will enable powerful ...
Ein DokumentmehrA revolution in laparoscopic training: KARL STORZ and VirtaMed leap beyond VR simulation
mehrMSD Expands Operations in Switzerland
Lucerne (ots) - - Company will open a new location in Zurich, focused on accelerating research, data and commercialization of our medicines and vaccines - Lucerne will remain the center of MSD's presence in Switzerland MSD (Merck Sharp & Dohme AG) today announced that it will establish a new office in Zurich, Switzerland, aimed at accelerating the ...
Ein DokumentmehrTransaction adds comprehensive gene editing capabilities and engine to drive expansion of Abcam's 'off-the-shelf' edited cell line portfolio
Cambridge, England and Milpitas, California (ots/PRNewswire) - Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC) for life science research and diagnostic ...
mehrZentiva Celebrates The Parc's Impressive Scientific Track Record in 2019
Prague (ots/PRNewswire) - Zentiva welcomed The Pharmaceutical Applied Research Center (The Parc) to their Prague headquarters to celebrate the first anniversary of The Parc Awards. The Parc is a unique research platform designed to prepare future generations of pharmaceutical scientists and engineers. Twenty-nine students are currently included in the program and an ...
mehrClaudine Blaser Egger to become a new member of the Helsana Executive Board
mehrSwissmedic grants approval for pembrolizumab (KEYTRUDA®) in combination with axitinib (Inlyta®) for first-line therapy of advanced renal cell carcinoma(1)
Lucerne (ots) - - Swissmedic approval is based on a significant benefit in overall survival with pembrolizumab in combination with axitinib compared to sunitinib in the Phase III study KEYNOTE-426 - Pembrolizumab is the first PD-1 inhibitor that has ...
Ein Dokumentmehr50% Savings on Cleaning Time, Water and Chemicals With Habasit's New Super HyCLEAN(TM) Plastic Modular Belt
Reinach, Switzerland (ots/PRNewswire) - World-leading belting supplier Habasit is launching its innovative Super HyCLEAN plastic modular belt range at IPPE 2020. Designed for poultry processing applications demanding the highest sanitation standards, the new belts' patented hygienic design significantly reduces ...
mehrCOMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression
London (ots/PRNewswire) - COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office. The patent covers the use of COMPASS's ...
mehrNovadiscovery raises series A financing to scale its in silico clinical trial platform - Debiopharm leads the round with EUR 5 million
Lausanne (ots) - - Novadiscovery pioneers the use of in silico clinical trials to predict drug efficacy and optimize clinical development, an approach meeting the strong expectations from pharmaceutical companies for faster and more efficient development, and benefiting from increased endorsement from health ...
mehrKnight Partners with Debiopharm for the Commercialization of Trelstar® in Canada
MONTREAL, CANADA and LAUSANNE, SWITZERLAND (ots) - Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada. ...
mehr- 7
Current exhibitions at the Museum im Lagerhaus
mehr Senzer's Pharmaceutical Inhaler Selected for Major Cannabinoid Patient Registry
London (ots/PRNewswire) - Senzer's pharmaceutical respiratory device will be used in Europe's first and biggest national medical cannabis registry, Project TWENTY21, in which an expected 20,000 patients will be enrolled by the end of 2021 creating the largest body of evidence for the efficacy of medical cannabis. Drug Science, the leading independent scientific body on ...
mehrKyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency
Tokyo (ots/PRNewswire) - Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto, "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson's disease (PD) ...
mehrAbcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability
Cambridge, England (ots/PRNewswire) - - Includes leading protein conjugation technologies and industry brands Lightning-Link® and CaptSure(TM) - Opportunity to combine Expedeon and Abcam's technologies to create new products to support research and diagnostic development Abcam plc, a global innovator in life ...
mehrLarge Real-World Data Confirm Safety and Effectiveness of LIXIANA® (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities
Munich (ots/PRNewswire) - · Results published in the European Heart Journal - Cardiovascular Pharmacotherapy (https://academic.oup.com/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz070/5644339?redirectedFrom=fulltext), showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 ...
mehrCOMPASS Pathways and King's College London Announce Results From Psilocybin Study In Healthy Volunteers
London (ots/PRNewswire) - COMP360 (psilocybin) was well tolerated in healthy volunteers and results support further investigation of simultaneous 1:1 therapeutic administration design COMPASS Pathways, a mental health care company, has reported that its COMP360 (psilocybin) was well-tolerated when administered to ...
mehrJan Adams Appointed Chief Scientific Officer for Grünenthal
Aachen, Germany (ots/PRNewswire) - Grünenthal announced today that Jan Adams, MD has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board effective 1 January 2020. Since July 2019, Jan has already served as acting CSO, leading the strategic re-alignment of Grünenthal's R&D organisation. Jan brings over 15 years of experience in healthcare and the biopharmaceutical industry. He joined ...
mehrUCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
Brussels (ots/PRNewswire) - - Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy ...
mehr